Glaukos
Sustainability Report and Carbon Intensity Rankings
Is Glaukos doing their part?
Their DitchCarbon score is 33
Glaukos has a DitchCarbon Score of 33 out of 100, indicating a lower performance in sustainability efforts. This score suggests that the company’s carbon intensity is relatively high, reflecting a greater environmental impact. Glaukos may need to implement more effective strategies to reduce its carbon footprint and improve its sustainability measures.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Glaukos, a company in the health and social services industry, has a carbon intensity ranking of low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Glaukos is situated in the United States, which has a low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint.
Unlock 30+ emissions data points on Glaukos
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Glaukos
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
8.56%
...this company is doing 8.56% worse in emissions than the industry average.
Founded in 1998 and headquartered in San Clemente, California, Glaukos Corporation operates within the health and social services industry, specializing in ophthalmic medical technology. The company is renowned for pioneering Micro-Invasive Glaucoma Surgery (MIGS) and introducing the iStent, one of the smallest FDA-approved medical devices. Glaukos continues to expand its portfolio with innovative micro-scale therapies aimed at improving the treatment and management of glaucoma.
emission intelligence's platform recommendations for Glaukos
Glaukos should consider implementing green procurement policies to source low-carbon energy and services, which could potentially reduce their emissions by 30%.
Bad news, Glaukos hasn't committed to SBTi climate goals yet.
Glaukos has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not defined or announced clear goals for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.